Mesoblast to host webcast for 2025 full year results

Mesoblast Limited will host a webcast on Friday, August 29, 2025, at 8:30 AM AEST to discuss its full year 2025 financial results and provide a corporate update. The webcast will cover operational highlights and financial results for the period ended June 30, 2025. Investors can access the live event via https://webcast.openbriefing.com/msb-fyr-2025/, with an archived version available on the company's website.

Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions, leveraging its proprietary mesenchymal lineage cell therapy technology. The company's therapies aim to modulate the immune system to reduce inflammatory processes. Its product, Ryoncil® (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease.

The company has established commercial partnerships in Japan, Europe, and China, and is developing additional cell therapies for indications such as SR-aGvHD in adults, biologic-resistant inflammatory bowel disease, heart failure, and chronic low back pain. Mesoblast holds an extensive global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection expected to last until at least 2041 in major markets.